Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial.

ABSTRACT:

Objective

To assess the efficacy of cannabis for the treatment of acute migraine.

Background

Preclinical and retrospective studies suggest cannabinoids may be effective in migraine treatment. However, there have been no randomized clinical trials examining the efficacy of cannabinoids for acute migraine.

Methods

In this randomized, double-blind, placebo-controlled, crossover trial, adults with migraine treated up to four separate migraine attacks, one each with vaporized (1) 6% Δ9-tetrahydrocannabinol (THC) (THC-dominant), (2) 11% cannabidiol (CBD) (CBD-dominant), (3) 6% THC + 11% CBD, and (4) placebo cannabis flower in a randomized order. Washout period between treated migraine attacks was ≥1 week. The primary endpoint was pain relief, and secondary endpoints were pa

SUBMITTER: Schuster NM 

PROVIDER: S-EPMC12872409 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature